Needham & Company Lifts PT on Alnylam Pharmaceuticals (ALNY) to $55

August 9, 2013 8:39 AM

Needham & Company analyst Alan Carr reiterated a Buy rating on Alnylam Pharmaceuticals (NASDAQ: ALNY) and raised his price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found